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Objective: This study is the first to investigate the relative effectiveness of cognitive–
behavioral therapy (CBT) compared with a selective serotonin reuptake inhibitor
(SSRI; sertraline) in a randomized, controlled trial on the treatment of anxiety
disorders in older adults.Method: Eighty-four patients 60 years of age and over with
a principal diagnosis of generalized anxiety disorder, panic disorder, agoraphobia,
or social phobia were randomly assigned to one of three conditions: 15 sessions of
CBT, pharmacologic treatment with an SSRI (sertraline; maximum dosage 150 mg),
or a waitlist control group. Participants completed measures of primary outcome
(anxiety) and coexistent worry and depressive symptoms at baseline, posttreatment,
and at three-month follow up. Results: Attrition rates were high in both treatment
groups. Consequently, findings are based on a relatively small sample of completers
(N52). Although both CBT and sertraline led to significant improvement in anxi-
ety, worry, and depressive symptoms both at posttreatment and at three-month follow
up, sertraline showed superior results on worry symptoms. Effect size estimates for
CBT were in the small to medium range both at posttreatment (mean d  0.42) and
at three-month follow up (mean d0.35), whereas effect sizes for sertraline fell into
the large range (posttreatment mean d  0.94 and three-month follow up mean d
1.02). The waitlist condition showed virtually no effects (posttreatment mean d 
.03). Conclusions: Our findings strongly suggest that the pharmacologic treatment
of late-life anxiety with SSRIs has not been given the proper attention in research to
date. (Am J Geriatr Psychiatry 2006; 14:255–263)
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Anxiety disorders are highly prevalent in olderadults1 and are associated with increased dis-
ability, a great negative impact on quality of life,2and
an inadequate use of healthcare services and psych-
otropic medication.3 Hersen and van Hasselt4have
argued for the development of psychosocial inter-
ventions, because the prescription of benzodiaz-
epines or even of safer psychotropic drugs such as
selective serotonin reuptake inhibitors (SSRIs) might
be problematic in older adults as a result of comor-
bidity with physical illness and potential negative
interactions with other drugs. Although this is a
valid argument, a pharmacologic approach should
not be discarded too hastily. In fact, randomized,
controlled trials of SSRIs in older adults with depres-
sion, although limited in number, have provided
evidence for the effectiveness and tolerability of
these drugs in older adults,5 even in the “older old.”6
Recently, the first randomized, placebo-controlled
trial evaluating the effectiveness of an SSRI (citalo-
pram) in the treatment of late-life anxiety has been
published,7 providing preliminary evidence for the
effectiveness and tolerability of this drug in anxious
older adults. However, this study awaits replication
in a larger sample.
Despite the argument for the development of psy-
chosocial interventions for the treatment of anxiety
in older adults, randomized, controlled trials in this
area are scarce. In mixed-age populations, empiric
evidence suggests that cognitive behavior therapy is
the most effective form of psychotherapy for anxiety
disorders.8 In recent years, several research efforts
have been made, providing some evidence for the
effectiveness of CBT in anxious older adults,9–12 but
the evidence is limited and not unequivocal.13
Our study is one of the first to investigate the
effectiveness of an SSRI (sertraline) in a randomized,
controlled trial of the treatment of anxiety disorders
in older adults. Sertraline was chosen because it has
been found to be effective and well tolerated both in
anxious mixed-age populations,14 and in depressed
older adults, even in case of comorbid medical ill-
ness.15 Also, in contrast to most research efforts in
this area, our study examines the effectiveness of
individual rather than group CBT in anxious older
adults, and it includes other anxiety disorders than
generalized anxiety disorder (GAD), namely panic
disorder, agoraphobia, and social phobia. Further-
more, the current investigation is the first to compare
CBT with a SSRI and a waitlist control group among
older adults with an anxiety disorder. This study was
approved by the Medical Ethical Review Board of the
University Medical Centre of Maastricht.
METHOD
Participants
Participants included 84 adults, aged 60 years and
over, with a principal Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition16 diagnosis of
GAD, panic disorder (either with or without agora-
phobia), agoraphobia without a history of panic dis-
order, or social phobia. Exclusion criteria were the
presence of an organic condition that provided a
contraindication for the use of SSRIs, current use of
antidepressant medication, a comorbid diagnosis of
alcohol dependency, current participation in psycho-
therapy, a history of psychosis or cognitive impair-
ment as indicated by clinical impression, and a score
of less than 26 on the Mini-Mental State Examina-
tion.17 Individuals stabilized on benzodiazepines
and their therapists were instructed not to change
their dose or type of medication for the duration of
the study. Individuals with comorbid depression,
dysthymia, or other anxiety disorders were not ex-
cluded from participation as long as their principal
diagnosis was GAD, panic disorder, agoraphobia,
or social phobia. Principal diagnosis was defined as
the most severely disabling disorder at the present
time. Participants were recruited from 2000 to 2003
through media announcements, distribution of infor-
mation leaflets in pharmacies, and clinics for general
practice and among referrals for treatment to com-
munity mental health centers and outpatient clinics
in five cities in the western and southern part of The
Netherlands. All participants were selected on the
basis of a structured diagnostic interview (SCID
2.018) administered by psychologists who had re-
ceived extensive training in this instrument.
Over a 3.5-year recruitment period, 160 subjects
received a diagnostic interview, of whom 115 people
(72%) fit the inclusion criteria and were invited to
participate in the research. Thirty-one patients (27%)
refused before providing preliminary data. Eighty-
four participants remained who were randomized
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into the study. Table 1 presents demographic and
diagnostic information about the sample.
Procedures
All participants read and signed an informed con-
sent form before being randomly assigned to one of
three conditions: 15 weeks of CBT (N42), sertraline
(N29), or a 15-week waiting period (N13). Ran-
domization procedures were as follows: One enve-
lope was filled with 62 labels stating “CBT,” 62 labels
stating “sertraline,” and 26 labels stating “waitlist.”
Based on the assumption that the waitlist condition
would show no effects, as is the case in comparable
treatment studies,10 we planned for fewer subjects in
the waitlist condition. This distribution would yield
maximum power to detect differences between CBT
and sertraline while still allowing for enough power
to differentiate between the active treatment condi-
tions and the waitlist condition.19 When a participant
had completed the screening procedure, the princi-
pal researcher would then blindly take one label out
of the envelope, which would then be excluded from
further randomization procedures. However, al-
though we allowed for a lengthy recruitment period
and great efforts were made to contact potential par-
ticipants, we could only assign 84 participants and
the remaining 66 labels were not used in the random-
ization procedure, which is why sample sizes are
unequal.
Trained psychologists and a trained research assis-
tant performed assessment interviews at pretest,
posttest, and at three-month follow up. Participants
in the CBT condition were treated individually by a
certified behavior therapist in 15 weekly one-hour
sessions. CBT consisted of relaxation training, cogni-
tive restructuring, and exposure. Treatment proto-
cols for CBT were derived from prevailing treatment
protocols of panic disorder,20 GAD,21 and social pho-
bia22 in mixed-age populations, which were adapted
for use with older adults (our CBT protocol consisted
of 15 sessions, allowing more attention to psycho-
education and repeated explanation and revision of
new information and newly learned coping skills).
Participating therapists took part in regular supervi-
sion meetings, which were led by certified supervi-
sors for behavior therapy. Therapists were repeat-
edly and explicitly instructed to contact their project
supervisor if they felt that they needed to deviate
from the protocol. Their supervisor would then talk
through the problem at hand to ensure that thera-
pists would adhere to the protocol.
In the sertraline condition, patients were treated
by a psychiatrist or a resident–psychiatrist in eight
20-minute sessions over a period of 15 weeks. The
TABLE 1. Descriptives of the Sample (before attrition)
Variable
Cognitive–Behavioral Therapy
(N  42)
Sertraline
(N  29)
Waitlist
(N  13)
Total
(N  84)
Age M (SD) 70.71 (6.58) 69.79 (5.49) 66.85 (5.96) 69.80 (6.20)
Duration of anxiety (years) M (SD) 23.33 (23.46) 29.86 (22.86) 27.22 (25.52) 26.16 (23.46)
Female N (%) 31 (73.8) 22 (75.9) 9 (69.2) 62 (73.8)
Married N (%) 23 (54.8) 18 (64.3) 6 (46.2) 47 (56.6)
Education
Low N (%) 19 (45.2) 12 (41.4) 5 (38.5) 36 (42.9)
Medium N (%) 8 (19.0) 10 (34.5) 5 (38.5) 23 (27.4)
High N (%) 15 (35.7) 7 (24.1) 3 (23.1) 25 (29.8)
Main diagnosis
Generalized anxiety disorder N (%) 14 (33.3) 10 (34.5) 5 (38.5) 29 (34.5)
Panic disorder* N (%) 17 (40.5) 16 (55.2) 5 (38.5) 38 (45.2)
Agoraphobia† N (%) 7 (16.7) 1 (3.4) 0 (0) 8 (9.5)
Social phobia N (%) 4 (9.5) 2 (6.9) 3 (23.1) 9 (10.7)
Comorbid diagnosis
Specific phobia N (%) 17 (40.5) 5 (17.2) 2 (15.4) 24 (28.6)
Other anxiety disorder N (%) 22 (52.4) 11 (37.9) 5 (38.5) 36 (42.9)
Depression N (%) 7 (16.7) 8 (27.6) 2 (15.4) 17 (20.2)
*With or without agoraphobia.
†Without a history of panic disorder.
M: mean; SD: standard deviation.
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protocol for sertraline included a dosage schedule
adapted for older adults, in which the starter dose
was lower (25 mg) and the dosage was built up more
gradually than in the customary procedure (up to a
minimum dose of 100 mg, which had to be reached
within four weeks, and a maximum dose of 150 mg
on the basis of tolerability and lack of clinical re-
sponse). Medication was maintained during three-
month follow up.
Measures
Outcome was assessed at posttreatment and at
three-month follow up. Pre- and posttreatment mea-
sures consisted of self-report measures and a struc-
tured interview. The interview consisted of the Ham-
ilton Anxiety Rating Scale (HARS,23 Cronbach
alpha0.82). The HARS was performed by two
members of the research group. Interrater agreement
on the HARS was measured in the initial stages of
the project. Weighted kappa was 0.58, constituting
moderate interrater agreement. Self-report measures
included the Beck Anxiety Inventory (BAI24; Cron-
bach alpha0.93) and the Dutch adaptation of the
Worry Domain Questionnaire (WDQ25; Cronbach al-
pha0.92). Items related to work situations in the
WDQ were omitted because they were not consid-
ered appropriate for an older population. Depressive
symptoms were measured with the Center for Epi-
demiological Studies Depression Scale (CES-D26;
Cronbach alpha0.90). The BAI and the HARS
should be considered as the primary outcome mea-
sures of this study. Assessment at three-month fol-
low up consisted solely of self-report measures,
which were distributed by mail (thereby excluding
the HARS) unless participants preferred a personal
interview with the researcher. Adverse effects in the
sertraline condition were measured with the Fawcett
checklist27 at the last session of the sertraline proto-
col.
Data Analysis
Analyses of variance and chi-squared tests were
used to compare participants assigned to the three
conditions on pretreatment demographic and clinical
variables, including number of coexistent diagnoses,
number of chronic diseases, and baseline anxiety
measurements.
Paired t-tests were used to establish improvement
within each condition. When data were not normally
distributed, Wilcoxon signed rank tests were per-
formed instead of paired t-tests. A random coeffi-
cient regression analysis was performed to establish
between-group differences with regard to improve-
ment over time.
Two measures of clinically significant change were
assessed: treatment response for anxiety, defined as
an improvement of 20% on two measures of anxiety
(BAI and HARS) and end-state functioning for anx-
iety, defined as a score of less than 10 on both the BAI
and the HARS (which equals a score within the
normal range). The 20% reduction criterion of treat-
ment response in a composite measure of self-report
and interview-rated instruments is frequently used
in the treatment literature of anxiety in older
adults.10–12 Rates of treatment response and end-
state functioning were only available for posttreat-
ment measurements.
RESULTS
Attrition
Ten (12%) of 84 patients refused participation in
the trial immediately after randomization, four of
whom were assigned to sertraline, three to CBT, and
three to the waitlist condition. Seventeen (23%) of the
remaining 74 participants dropped out of the trial
before completing CBT (N9), sertraline (N7), or
waitlist conditions (N1), culminating in a total at-
trition rate of 32% (27 of the initial sample of 84
participants). There were no significant differences in
attrition rates across treatment groups. One partici-
pant randomized to sertraline switched to venlafax-
ine in one of the first weeks of treatment as a result of
adverse side effects and was excluded from outcome
analysis. For completer analyses, data from 56 par-
ticipants were available who completed CBT (N
30), sertraline (N17), and waitlist conditions (N
9). Another four participants failed to turn in their
pretreatment questionnaires, although they did com-
plete the HARS interview, one of which was as-
signed to sertraline, two to CBT, and one to the
waitlist condition. Reasons mentioned for dropout
from CBT included: treatment was found to be too
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straining or confronting (N2) or too time-consum-
ing (N2); participants did not agree with the treat-
ment rationale (N5); and spontaneous remission of
symptoms (N4). Reasons mentioned for dropout
from sertraline included: long-term illness (N1),
deceased before starting medication (N1), side ef-
fects (N4), anticipated side effects before actually
starting medication (N1), and spontaneous remis-
sion of symptoms (N1).
No significant differences between dropouts and
completers were found for sex, age, marital status,
level of education, main psychiatric diagnosis, med-
ication use, chronic illness, or duration of symptoms.
Noncompleters were found to have a higher score at
pretreatment on the HARS (t2.33, df79, p0.05),
but not on any of the other outcome variables.
At three-month follow up, four participants (9%)
refused to fill in their questionnaires. During follow
up, three participants (two CBT and one sertraline
participant) were given an alternative psychophar-
macologic treatment because their symptoms had
not sufficiently improved. These participants were
excluded from follow-up analyses, leaving a sample
of 39 participants (25 CBT and 14 sertraline) who
were included in follow-up analyses. Waitlist partic-
ipants were not included in follow-up analyses, be-
cause they were reassigned to one of the active treat-
ment conditions after completing the 15-week
waiting period.
Differences Between Therapy Groups at
Pretreatment
A comparison on all pretreatment demographic
and clinical variables, including the distribution of
principal diagnosis and severity of anxiety symp-
toms at baseline using 2 tests and analyses of vari-
ance, demonstrated no significant differences (Table
1). After attrition, sertraline participants had a higher
rate of comorbid depression at baseline than CBT or
waitlist participants (2  7.182, p 0.05). Therefore,
the rate of comorbid depression was entered into
completer analyses as a confounder.
Treatment Outcome
Paired t-tests were performed to assess within-
treatment effects for each group between pretreat-
ment and posttreatment and between pretreatment
and three-month follow up. Results from Wilcoxon
signed rank tests showed the same results. Table 2
presents t and p values, effect size estimates, and
percentage of change over time by condition.
At posttreatment, both CBT and sertraline partici-
pants had improved significantly on every outcome
measure. Improvement was largely maintained dur-
ing three-month follow up. Participants in the wait-
list condition did not show significant change on any
of the outcome measures. Effect size estimates were
calculated as the difference between mean pre- and
posttreatment scores divided by the pooled standard
deviations from the baseline and posttreatment
scores (Cohen’s d28). In general, effect sizes for CBT
were in the small to medium range both at posttreat-
ment (mean d  0.42) and at three-month follow up
(mean d0.35), whereas effect sizes for sertraline
were in the large range (posttreatment mean d 0.94
and three-month follow up mean d1.02). The wait-
list condition showed virtually no effects (posttreat-
ment mean d  0.03).
Random coefficient regression analysis of patients
completing treatment revealed significant
group*time interactions on the WDQ (2  14.54,
df3, p 0.001) and the HARS (213.82, df2, p
0.01), but not on the BAI (25.81, df3, p0.12)
or the CES-D (27.05, df3, p0.07). Specific
group*time interactions were calculated after the re-
moval of main effects. These analyses showed that
both CBT (mean difference [MD]: -5.97, standard
error [SE]: 2.16, df37, p 0.01) and sertraline com-
pleters (MD: -9.26, SE: 2.36, df24, p 0.001)
showed greater improvement than waitlist compl-
eters on the HARS. Sertraline completers showed
greater improvement on the WDQ than waitlist com-
pleters (MD: -12.85, SE: 4.50, df24, p 0.01),
whereas CBT completers did not (MD: -4.12, SE: 4.24,
df37, p0.34). Furthermore, sertraline completers
showed greater improvement on the WDQ than CBT
completers, both from pre- to posttreatment (MD:
8.73, SE: 3.04, df45, p 0.01) and from pretreat-
ment to follow up (MD: 10.11, SE: 3.13, df45, p
0.01). Sertraline completers did not show greater
improvement on the HARS than CBT completers
(MD: -3.29, SE: 1.76, df45, p0.07).
An intent-to-treat analysis revealed significant
group*time interactions on the HARS (28.44, df
2, p 0.05), but not on any of the other outcome
measures. Specific group*time interaction analyses
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revealed that sertraline participants showed greater
improvement on the HARS than waitlist participants
(MD: -5.92, SE: 2.41, df39, p 0.05) but not CBT
participants (MD: -2.97, SE: 1.80, df68, p0.10).
CBT participants did not show greater improvement
than waitlist participants on the HARS (MD: -2.95,
SE: 2.24, df53, p0.19).
Treatment Response and End-State Functioning
At posttreatment, 44% of CBT participants, 57% of
sertraline participants, and one waitlist participant
(11%) could be classified as treatment responders.
Separate 2 analyses of the three group comparisons
revealed significant differences in treatment re-
sponse rates between sertraline and waitlist (2
4.871, p 0.05), but not between CBT and waitlist
(23.251, p0.08) or between CBT and sertraline
(20.601, p0.33).
Before treatment, 2 analyses did not reveal any
significant differences between conditions with re-
gard to level of functioning for anxiety. After treat-
ment, 48% of CBT participants, 47% of sertraline
participants, and none of the waitlist participants fit
criteria for high end-state functioning (26.882, p
0.05).
Adverse Effects in the Sertraline Group
Adverse effects that were reported by medication
completers (N17) and that were deemed moderate
to very severe by the (resident) psychiatrist at the last
session of treatment were anorexia (N1; 5.9%), tin-
nitus (N1; 5.9%), stiffness (N1; 5.9%), ataxia (N
1; 5.9%), dry mouth (N1; 5.9%), hypertension (N
1; 5.9%), heart palpitations (N2; 11.8%), miction
problems (N2; 11.8%), agitation (N2; 11.8%), in-
crease in appetite (N2; 11.8%), tremors (N2;
11.8%), nausea/vomiting (N2; 11.8%), drowsiness
(N2; 11.8%), fatigue (N3; 17.6%), headache (N
3; 17.6%), anxiety and nervousness (N3; 17.6%),
transpiration (N3; 17.6%), insomnia (N3; 17.6%),
reduction of frequency of sex (N4; 23.5%), prob-
lematic erection or lubrication (N4; 23.5%), ab-
sence of orgasm (N4; 23.5%), lessened intensity of
orgasm (N4; 23.5%) reduction of libido (N5;
29.4%), depression (N5; 29.4%), and pain (N5;
29.4%).TA
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DISCUSSION
Implications of Our Findings
Our study was the first to compare the effective-
ness of a SSRI with CBT for the treatment of anxiety
disorders in older adults. We found that although
both treatments led to significant improvement on all
measures of outcome, sertraline completers showed
greater improvement on symptoms of worry as mea-
sured with the WDQ. Moreover, effect sizes for CBT
were relatively small (0.310.58), whereas effect
sizes for sertraline fell into the large range
(0.851.08). However, treatment response rates and
rates of high end-state functioning were not signifi-
cantly different between treatment groups. Some of
our findings run contrary to what one might expect
on the basis of results from similar studies in mixed-
age populations. In most randomized, controlled tri-
als of the treatment of anxiety disorders, SSRIs and
CBT are found to be equally effective.8
Our findings indicate that the reluctant attitude of
both researchers and general practitioners toward
the use of SSRIs in late life may be unjustified. Given
the fact that four participants (14%) did report ad-
verse effects to sertraline as a reason for dropping
out of the trial, which is comparable to dropout rates
resulting from side effects in studies of sertraline for
depression in late life (11%–19%15,29,30), patients
should be closely monitored and better informed on
what to expect from an SSRI by their physician to
increase treatment adherence.
In concordance with most other treatment studies
in late-life anxiety,9,10,12 effect sizes for CBT were
substantially lower and attrition rates for both CBT
and sertraline were considerably higher than those
found in comparable treatment studies in mixed-age
populations (mean attrition rate approximately
10%).31 These findings imply that it is important that
we find ways to increase treatment adherence in
anxious older adults.
CBT did not perform as well as expected on the
basis of similar treatment studies in older adults. The
only comparable trial that investigated individual
format CBT in anxious older adults (with mixed
anxiety disorders) was the study by Barrowclough et
al.,11 which yielded more positive results for CBT
than our study. However, participants in Barrow-
clough’s study were mostly treated in their own
homes, which may have positively influenced both
the effectiveness of treatment as well as treatment
adherence. Also, 51% of participants in the Barrow-
clough study used antidepressants during the treat-
ment phase, which may well have biased the results.
Although treatment response rates were higher in
the Barrowclough study (71% at 12-month follow
up), effect sizes were also in the small to medium
range at 0.34. Also, participants in other treatment
studies9,10,12 were mostly well educated, whereas in
our study, 45% of CBT participants had only finished
primary school.
Finally, problems with homework completion may
play an important role in the moderate outcome of
CBT in our study. Although we did not measure
homework completion in a standardized manner, we
do recall that one of the topics that came up fre-
quently in our supervision meetings was the trouble
that therapists encountered in getting participants to
complete the homework. Reasons for this phenome-
non were related to participants’ disbelief in the use-
fulness of homework assignments, insecurity and
difficulties in dealing with assignments, and lack of
time.
Limitations
The main limitation to the present study was it is
lack of power as a result of large attrition rates and
the differences in sample size between conditions,
which resulted from the fact that our randomization
procedures were unsuccessful as a result of unfore-
seen recruitment problems. As a consequence, our
study is not as persuasive as it might have been if
other randomization procedures were used.
Also, the follow-up period of this study was rela-
tively short (three months), considering the fact that
in mixed-age populations, the outcome of CBT, tends
to improve after termination of treatment.31 How-
ever, our results showed no improvement of CBT
outcome during three-month follow up.
Although completer analyses showed some signif-
icant differences in treatment effect between CBT
and sertraline, it should be noted that intention-to-
treat analyses did not yield the same results.
The fact that the use of sertraline was largely main-
tained during follow up may have biased the com-
parison with CBT, because evidence from younger
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populations suggests that anxiety symptoms tend to
recur after termination of pharmacologic treatment.8
Unfortunately, the Dutch review board for medical
ethics did not grant us permission to allocate older
adults to a placebo condition. As a consequence, we
could not reliably establish whether treatment effect
and reported side effects should be attributed to
sertraline. The fact that treatment in our study lasted
for 15 weeks (more than twice the length of most
pharmacologic studies in younger populations) and
the fact that treatment results were largely main-
tained during three-month follow up makes it less
plausible that treatment effect is attributable to a
placebo effect.
Relating to the inclusion of different anxiety dis-
orders, the fact that we chose not to include measures
on phobic avoidance or the frequency of panic at-
tacks might be considered as a limitation. However,
such measures would not have been appropriate for
all subjects, which is why we chose two outcome
measures for general anxiety symptoms, the BAI and
the HARS, as the main outcome measures of this
study. Also, the inclusion of different anxiety disor-
ders might limit the generalizibility of our findings.
The inclusion of agoraphobia without panic disorder
in particular might induce comments on the fact that
there is no specific evidence on the effectiveness of
SSRIs for the treatment of this disorder. However,
repeated outcome analyses excluding those with a
main diagnosis of agoraphobia without panic disor-
der yielded similar results.
Finally, it should be noted that assessment was not
blind and that follow-up assessments were solely
based on self-report measures.
Recommendations and Conclusions
Future randomized, controlled trials might incor-
porate other psychologic interventions that might be
more suitable for use with older adults (such as
reminiscence therapy, which has shown positive re-
sults for the treatment of late-life depression32). More
research is needed to firmly establish if and what
modifications are needed for the appropriate use of
CBT with an older population. Finally, our findings
strongly suggest that the pharmacologic treatment of
late-life anxiety with SSRIs has not been given the
proper attention in research to date.
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